NEW YORK, Oct. 02, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Dr. Reddy’s Laboratories Ltd. (NYSE:RDY) who purchased shares between June 17, 2015 and August 10, 2017. The action, which was filed in the United States District Court for the District of New Jersey, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (1) Dr. Reddy’s lacked an effective corporate quality system; and (2) as a result, defendants’ public statements were materially false and misleading at all relevant times.
On November 6, 2015, Dr. Reddy’s announced that it had received a warning letter issued by the U.S. Food and Drug Administration concerning inadequate quality control standards at three of Dr. Reddy’s manufacturing plants in India. Then on August 10, 2017, Dr. Reddy’s disclosed that the Regierung von Oberbayern (the district government of Upper Bavaria) did not renew the good manufacturing practices compliance certificate of a manufacturing unit of Dr. Reddy’s German subsidiary Betapharm Arzneimittel, located in India.
Shareholders have until October 24, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sb/dr-reddys-laboratories-ltd?wire=3.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com


MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
OpenAI Addresses Security Vulnerability in macOS App Certification Process
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 



